Tag: BIO101
Biophytis launches phase 2 OBA clinical study in obesity with BIO101 (20-hydroxyecdysone) – 04/08/2024 at 11:14 p.m.
Paris, France, Cambridge (Massachusetts, United States), April 8, 2024 – 11:00 p.m. – Biophytis SA (Nasdaq CM: BPTS, Euronext Growth Paris: ALBPS), (“Biophytis” or the “Company”), a biotechnology company clinical…
Biophytis and Innovation Solutions Pharma sign a partnership to accelerate market access for Sarconeos (BIO101) in Brazil – 10/30/2023 at 06:00
Biophytis SA (Nasdaq CM: BPTS, Euronext Growth Paris: ALBPS), (“Biophytis”), a clinical-stage biotechnology company specializing in the development of treatments that aim to slow down the degenerative processes linked to…
Biophytis and Skyepharma sign a partnership for the production of Sarconeos (BIO101) – 09/25/2023 at 07:00
– Biophytis SA (Nasdaq CM: BPTS, Euronext Growth Paris: ALBPS), (“Biophytis”), a clinical-stage biotechnology company specializing in the development of treatments that aim to slow down degenerative processes linked to…
Biophytis and SEQENS sign a partnership for the production of the active ingredient of Sarconeos (BIO101) – 07/18/2023 at 07:00
Paris, France, July 18, 2023 – 7:00 a.m. – Biophytis SA (Nasdaq CM: BPTS, Euronext Growth Paris: ALBPS), (“Biophytis”), a clinical-stage biotechnology company specializing in the development of treatments that…
Biophytis presents the clinical results of Sarconeos (BIO101) in sarcopenia at the 16th international SCWD congress – 06/19/2023 at 07:00
Paris (France) and Cambridge (Massachusetts, United States), June 19, 2023 – 07:00 a.m. – Biophytis SA (Nasdaq CM: BPTS, Euronext Growth Paris: ALBPS), (“Biophytis” or the “Company”), a biotechnology company…
Biophytis presents the development of Sarconeos (BIO101) as a drug candidate in rare neuromuscular diseases at the Muscular Dystrophy Association (MDA) clinical and scientific conference – 03/20/2023 at 08:00
Paris (France), Cambridge (Massachusetts, United States)), March 20, 2023, 8:00 a.m. CET – Biophytis SA (NasdaqCM: BPTS, Euronext Growth Paris: ALBPS) (the “Company” or “Biophytis”), a biotechnology company specializing in…
Biophytis provides an update on the development of Sarconeos (BIO101) in Covid-19 at the 4th Annual Longevity Therapeutics Summit Results of the COVA phase 2-3 study expected in the 3rd quarter of 2022 – 07/04/2022 at 08:00
Paris, France, Cambridge (Massachusetts, USA), July 4, 2022 – 8:00 a.m. – Biophytis SA (Nasdaq CM: BPTS, Euronext Growth Paris: ALBPS), (“Biophytis” or the “Company”), a stage clinic specializing in…
Biophytis presents the development of Sarconeos (BIO101) in Phase 3 in the treatment of Sarcopenia at the 15th international SCWD congress – 06/27/2022 at 23:00
Paris, France, Cambridge (Massachusetts, United States), June 27, 2022 – 11:00 p.m. – Biophytis SA (Nasdaq CM: BPTS, Euronext Growth Paris: ALBPS), (“Biophytis” or the “Company”), a biotechnology company at…
Biophytis Presents the Phase 3 Development of Sarconeos (BIO101) in the Treatment of Sarcopenia at the 15th SCWD International Congress
Biophytis presents the development of Sarconeos (BIO101) in Phase 3 in the treatment of Sarcopenia at 15th international SCWD congress Paris, France, Cambridge (Massachusetts, United States), June 27, 2022 –…
Biophytis presents the Sarconeos (BIO101) development program in sarcopenia at the 12th annual International Congress on Frailty and Sarcopenia (ICSFR), in Boston from April 20 to 22, 2022 – 04/19/2022 at 08:00
Paris, France, Cambridge (Massachusetts, United States), April 19, 2022 – 8:00 a.m. – Biophytis SA (Nasdaq CM: BPTS, Euronext Growth Paris: ALBPS), (“Biophytis” or the “Company”), a biotechnology company at…